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Results from the completed treatment analysis of the ATAC (Arimidex, Tamoxifen alone or in combination) trial indicated that
anastrozole was significantly superior to tamoxifen in terms of efficacy and safety in the adjuvant treatment of postmenopausal
women with hormone receptor-positive (HRþ) early breast cancer. On the basis of these results, this study estimated the cost-
effectiveness of anastrozole vs tamoxifen, from the perspective of the UK National Health Service (NHS). A Markov model was
developed using the 5-year completed treatment analysis from the ATAC trial (ISRCTN18233230), as well as data obtained from
published literature and expert opinion. Resource utilisation data and associated costs (2003–4 UKd) were compiled from standard
sources and expert opinion. Utility scores for a number of health states were obtained from a cross-sectional study of 26
representative patients using the standard gamble technique. The utility scores were then inserted into the model to obtain cost per
quality adjusted life-year (QALY) gained. Costs and benefits were discounted at recommended annual rates of the UK Treasury
(3.5%). Modelled for 25 years, anastrozole, relative to generic tamoxifen, was estimated to result in 0.244 QALYs gained per patient
at an additional cost of d4315 per patient). The estimated incremental cost-effectiveness of anastrozole compared with tamoxifen
was d17656 per QALY gained. There was a greater than 90% probability that the cost-effectiveness of anastrozole was below
d30000 per QALY gained and of the order of 65% that it was below d20000 per QALY gained. The results were robust to all
parameters tested in sensitivity analysis. Compared with commonly accepted thresholds, anastrozole is a cost-effective alternative to
generic tamoxifen in adjuvant treatment of postmenopausal women with HRþ early breast cancer from the UK NHS perspective.
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Breast cancer is common among women in the United Kingdom,
causing the death of around 70 women per 100000 aged 50–69
years on an annual basis (Peto et al, 2000). Treatment of this
common malignancy is a significant economic burden. For
example, the annual cost to the UK National Health Service
(NHS) of drug therapy for 13200 patients with hormone receptor-
positive (HRþ) early breast cancer has been estimated at d64.6
million (Benedict and Christie, 2003). Tamoxifen is an established
adjuvant treatment option in this regard (Early Breast Cancer
Trialists’ Collaborative Group, 1998; Early Breast Cancer Trialists’
Collaborative Group, 2005). However, treatment with tamoxifen
has been associated with serious safety concerns (Reddy and
Chow, 2000), including thromboembolic disorders (Love et al,
1991) and increased risk of the development of endometrial cancer
(Fisher et al, 2001). Consequently, there is a need for new
hormonal treatment options with improved safety and efficacy,
particularly in terms of avoiding or delaying costly disease
recurrences (Lamerato et al, 2004).
Anastrozole is an aromatase inhibitor that has proved sig-
nificantly superior to tamoxifen as adjuvant treatment for
postmenopausal women with HRþ early breast cancer. This was
apparent in terms of more favourable disease-free survival (hazard
ratio 0.83, P¼0.005) and longer time to recurrence (Hazard Ratio
0.74, P¼0.0002) in the completed treatment analysis of the
ATAC (Arimidex, Tamoxifen Alone or in Combination) trial
(ISRCTN18233230), which was performed in postmenopausal
women with early operable breast cancer who had completed
primary therapy and were eligible for adjuvant hormonal therapy
(ATAC Trialists’ Group, 2005). Anastrozole was also associated
with a more favourable safety profile vs tamoxifen, including a
significantly lower incidence of endometrial cancer, thrombo-
embolic events and vaginal bleeding/discharge albeit with increased
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srisk of arthralgia and bone fracture (ATAC Trialists’ Group, 2005).
These results confirmed the previously reported findings at a
median 47 months’ follow-up (The ATAC Trialists’ Group, 2003).
Furthermore, in a subprotocol of the ATAC trial, it was shown that
the superiority of anastrozole over tamoxifen was achieved without
a detrimental impact on overall quality of life (Fallowfield et al,
2004; Cella et al, 2006).
The findings of the ATAC trial demonstrate that anastrozole
(1mg daily) provides an effective and well-tolerated alternative to
tamoxifen (20mg daily) for adjuvant treatment of postmenopausal
women with HRþ early breast cancer. Subsequently, the ASCO
Technology Assessment recommended that optimal adjuvant
hormonal therapy for a postmenopausal woman with HRþ early
breast cancer should now include an aromatase inhibitor either as
initial therapy or after treatment with tamoxifen (Winer et al,
2005). However, the higher acquisition cost of anastrozole, against
a background of increasing fiscal constraints on healthcare
budgets, could limit the adoption of this agent as has occurred
for other new therapeutic interventions in the United Kingdom
and elsewhere. Consequently, healthcare decision makers such as
the National Institute for Health and Clinical Excellence (NICE)
and the Scottish Medicines Consortium (SMC) recognise that value
for money should be a key criterion for deciding which new
healthcare interventions should be reimbursed from the limited
NHS budget. Evidence from cost-effectiveness analysis, preferably
over the expected lifetime of the patient population, is formally
used as part of the technology appraisal and subsequent guidance
issued to the NHS. On the basis of the evidence submitted,
anastrozole has now been recommended by both NICE and the
SMC as an option for the adjuvant treatment of early oestrogen-
receptor positive invasive breast cancer in postmenopausal
women. On the basis of discount rates that were applicable prior
to 2004 (6% for costs, 1.5% for benefits), NICE estimated that the
cost per quality-adjusted life years (QALY) of anastrozole
compared with tamoxifen (d12310/QALY) lay below the currently
accepted thresholds under which interventions are considered to
be cost-effective (d20K to d30K/QALY). This study uses the latest
recommended discount rates of 3.5% for both costs and benefits
and is therefore in accordance with the latest guidelines from NICE
(National Institute for Health and Clinical Excellence, 2004).
MATERIALS AND METHODS
In the ATAC trial, postmenopausal women with early (invasive,
operable) breast cancer who had completed primary therapy
(surgery7radiotherapy7chemotherapy) and who were eligible for
adjuvant hormonal therapy were randomised to receive either
anastrozole or tamoxifen (or both) for up to 5 years (ATAC
Trialists’ Group, 2005). Since the combination arm demonstrated
no benefit over tamoxifen in terms of efficacy or safety, this arm
was discontinued and the present analysis is restricted to the two
monotherapy arms.
Design of the Markov model, inputs and assumptions
On the basis of the latest results from the ATAC trial, as well as
data derived from interviews with UK oncologists and published
literature, a probabilistic Markov model (Sonnenberg and Beck,
1993) was developed to project outcomes for a hypothetical cohort
of 1000 postmenopausal women (mean age 64 years) with HRþ
early breast cancer in the United Kingdom. Markov models assume
that a patient is always in one of a finite number of discrete health
states and all events are represented as transitions from one state
to another. In this study, the Markov model was evaluated as a
Monte Carlo simulation. The model projected outcomes over an
actuarial time horizon of 25 years. At any time point, women in the
model are in one of seven health states: (1) on adjuvant endocrine
treatment (i.e. anastrozole or tamoxifen); (2) on an unplanned
switch of adjuvant treatment; (3) off-treatment, in remission; (4)
with distant recurrence; (5) with local/regional recurrence; (6)
dead due to breast cancer or (7) dead due to other causes. All
women enter the model in the ‘on adjuvant treatment’ health state
(Figure 1). Women would then move between the health states at
3-month intervals during the first 5 years (when they received
primary adjuvant treatment with anastrozole or tamoxifen) and at
6-month intervals thereafter (Figure 1).
Event rates for recurrence and breast cancer-related death were
derived from the ATAC trial and extrapolated to 25 years using
Weibull parametric methods (Cook et al, 1969). This involves
postulating a Weibull distribution for time to recurrence and
estimating the parameters of the distribution from the data. In this
study, a Weibull curve was fitted to the time to recurrence data for
each treatment arm of ATAC. The Weibull regressions were
produced using the LIFEREG procedure of the SAS statistical
package. The intercept was estimated as 9.17, the scale parameters
as 0.83 and the coefficient of the treatment effect as 0.25. The curve
provided a good fit to the data as shown in Figure 2. The
probability of recurrence, based on the Weibull curves, was then
extrapolated to 10 years from initiation of treatment based on an
assumption that the benefit of anastrozole would carry over to 5
years following the end of treatment. This key assumption was
based on the continuing divergence of the recurrence curves
observed in the completed treatment analysis of the ATAC trial
(median 68 months’ follow-up) (ATAC Trialists’ Group 2005) and
the durable treatment benefit previously observed with tamoxifen
(Early Breast Cancer Trialists’ Collaborative Group, 2005).
A Weibull curve was also fitted to the ATAC time to recurrence
data, pooled across the treatment arms. Using the LIFEREG
procedure of the SAS statistical package, the intercept was
estimated as 9.29 and the scale parameter as 0.83. The curve
provided a good fit to the data as shown in Figure 3. The pooled
curve was used to calculate probability of recurrence from 10 to 25
years from initiation of treatment based on an assumption that the
time-dependent rates of recurrence after 10 years would be the
same for both anastrozole and tamoxifen. The Weibull curves
provided a good fit to the ATAC trial data and formed the basis for
estimating the probability of a patient moving to the recurrence
health state, at each cycle in the Markov model, over a 25-year time
horizon. The recurrent patients in the model had either a local-
regional recurrence or distant recurrence based on the proportion
of the two types in the ATAC trial. Progression of patients from
recurrence was modelled parsimoniously (see Figure 1). Patients
with local-regional recurrence could stay in that state, progress to
distant metastasis, or die, either of breast cancer or for other
causes. Distant metastatic patients could survive, or die. A 25-year
time horizon was chosen for the model because of the need to
capture the long-term benefits of treatment. At the same time due
to average age at diagnosis and the life expectancy of post-
menopausal women with early breast cancer 25 years represents a
time period over which the majority of patients would have died. A
longer time horizon would have had very little impact on the
results. In the basecase analysis it was assumed that the recurrence
curves continued to show incremental benefit for anastrozole out
to 10 years from initiation of treatment.
The probabilities of other variables used in the model (e.g.
adverse events, withdrawal and switching rates) were derived from
the 5-year results of the ATAC trial (ATAC Trialists’ Group, 2005),
other published sources, and an expert panel consisting of six
practising UK breast cancer specialists. Other outcome probabil-
ities used in the model for the probabilistic sensitivity analysis,
with specified distributions and the sources are shown in Table 1.
Adverse events were assumed only to occur during the 5-year
treatment period, except for a few events that, in the opinion of the
expert panel, patients could remain at risk of beyond treatment
completion. In particular, based on the same expert opinion, the
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smodel assumed that the risk of hip fracture and endometrial
cancer extended for an additional 3 years and that the risk of
thromboembolic events extended for an additional 6 months.
Hysterectomy rates obtained from the ATAC trial (5.1% with
tamoxifen and 1.3% with anastrozole), together with their
associated costs and utilities, were also included in the model.
To reflect routine clinical practice in the United Kingdom, the cost
of endometrial cancer monitoring in patients receiving tamoxifen
was excluded and the cost of adding bisphosphonate therapy in
anastrozole-treated patients was included. It was assumed that 5%
of patients received bisphosphonates during anastrozole treat-
ment, based on bisphosphonate usage recorded in the ATAC trial
and supported by expert opinion. The uncertainty in the above
assumptions was accounted for in the sensitivity analysis.
Age-specific mortality data for women in the general population
were obtained from the UK Office of National Statistics (2002). It
was assumed that the risk of death for causes other than breast
cancer (including those related to adverse events) was the same for
both treatment groups. Mortality statistics from potentially fatal
adverse events (e.g. endometrial cancer, thromboembolic events,
Die − other causes
On treatment
Life − threatening AEs
Non life − threatening AEs
Switch
Relapse/recur
Distant cancer
Local/regional cancer
Switch treatment
Off treatment, remission
Distant cancer
Distant cancer
Distant cancer
Distant cancer
Distant cancer
Distant cancer
Remain in switch
Remain off treatment,
remission
Remain on treatment
Remain on treatment
Local/regional cancer
Local/regional cancer
Local/regional cancer
Local/regional cancer
Local/regional cancer
Local/regional cancer
Remain on treatment
Off treatment, remission
Off treatment, remission
Off treatment, remission
Switch treatment
No relapse/no recur
No relapse/no recur
No relapse/no recur
No relapse/no recur
No relapse/no recur
Relapse/recur
Relapse/recur
Relapse/recur
Relapse/recur
Remain
Switch
Remain
No AEs
Relapse/recur
Die − other causes
Die − other causes
Die − other causes
Die − other causes
Die − other causes
Die due to breast cancer
Die due to breast cancer
Die due to breast cancer
Distant cancer
Local/regional
cancer
Off treatment,
remission
Switch treatment
Treat with
tamoxifen or
anastrozole
Survive
Survive
Survive
Survive
Relapse/recur
No relapse/no recur
No relapse/no recur
Develop distant cancer
Remain in distant cancer
Remain in local/regional cancer
Survive
Figure 1 The Markov decision model for health status. AEs, adverse events.
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ship fractures) were also retrieved from the UK Office of National
Statistics database and incorporated into the model. It was
assumed that mortality due to hip fractures increased with
increasing age while death due to other adverse events remained
constant over time.
Resource utilisation and costs
Data on resource utilisation were obtained from structured
interviews with the expert panel and, where possible, published
literature. This included data on: the medical management
required during treatment and follow-up and when patients were
off-treatment (due to remission or adverse events); the medical
management required at diagnosis and during disease recurrence
(local/regional and distant); the treatment of serious adverse
events requiring hospitalisation and non-serious adverse events;
and palliative care requirements (Table 2). Costs were then
assigned to each unit of resource to estimate total costs. Unit cost
information was obtained from MEDTAP’s unit cost database and
published sources, the British National Formulary (2003/2004) and
NHS reference costs (Department of Health, 2003). The model only
included direct medical costs.
Drug costs were derived from standard sources (anastrozole,
d68.56 per 28-tablet pack (MIMS, 2005); tamoxifen, d2.24 per
30-tablet pack (British National Formulary, 2003/2004)). These were
not varied in the model. Future costs and benefits were discounted
at the annual rate of 3.5%, the rate recommended by the UK
Treasury (National Institute for Health and Clinical Excellence).
Calculating quality-adjusted life years
A cross-sectional study of 26 representative UK patients with early
or advanced breast cancer (mean age 68 years) was used to derive
quality-of-life weights (utilities) for insertion into the model. Most
patients had HRþ, node-negative disease and were presently
receiving tamoxifen; a minor proportion was receiving anastrozole
(no patient was receiving treatment within the ATAC trial).
Utilities for different health states were elicited using a chained
standard gamble method that compared the health states to perfect
and worse health and then worse health against perfect health and
death (Torrance, 1986). Table 3 summarises the mean utility scores
for the 14 health states plus the score for the current health state.
These utility scores were assigned to the patients in the
corresponding health states in the model and used to estimate
the number of QALYs gained.
Analysis
The objective of the cost-utility analysis was to evaluate the
economic consequences of choosing anastrozole over tamoxifen,
in terms of costs, QALYs gained and the cost per QALY gained.
The incremental cost per QALY gained was calculated as the
difference in cost between anastrozole and tamoxifen divided by
the difference in QALYs using a Monte Carlo simulation of 5000
runs (Crystal Ball
s 2000). Results were presented as means for
costs and effects separately, and as a cost-effectiveness accept-
ability curve. The latter curve shows the probability that the
incremental cost per QALY gained lies below a specified monetary
threshold (van Hout et al, 1994).
To assess the robustness of the study results with respect to the
base-case assumptions, key parameters and assumptions were
varied in a sensitivity analysis. In particular, the analysis was
carried out probabilistically.
b-Distributions are commonly accepted to be used to model
transition probabilities (Briggs, 2001). Parameters of the b were
calculated based on patient numbers in the trial. g-Distributions
were assumed to be a good fit for skewed and non-negative total
cost data for each item (see Table 2). The overall level of
uncertainty in the results was expressed as a cost-effectiveness
acceptability curve. The acceptability curve provides an exact fit
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Figure 2 Weibull model fitted to each treatment arm of ATAC.
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Figure 3 Weibull model fitted to the pooled ATAC data.
Table 1 Outcome probabilities used in the model
Anastrozole Tamoxifen Distribution Probabilistic parameters
Distant recurrences as a proportion of all recurrences during recurrence benefit
a 0.66 0.60 b Anastrozole: a, 186; b,9 6
Tamoxifen: a, 222, b, 148
Adverse events
b
Life-threatening 0.047 0.066 b Anastrozole: a, 142; b, 2950
Tamoxifen: a, 201, b, 2893
Non life-threatening 0.698 0.657 b Anastrozole: a, 2163; b, 929
Tamoxifen: a, 2037, b, 1057
None 0.255 0.277 Remainder
Following local/regional recurrence
Distant metastases-free at 5 years
c 0.52 ba , 73; b,6 7
Distant metastases-free after 5 years
d 0.77 ba , 91; b,2 7
Death due to breast cancer
e 0.222 ba , 26; b, 140
Following distant recurrence
Overall survival at 2 years
f 0.50 ba , 155; b, 155
aNote that the overall number of recurrences was lower in the anastrozole arm (282) than in the tamoxifen arm (370); percentages are calculated based on recurrences
occurring as a first event, estimated from ATAC data (anastrozole 186, tamoxifen 222), and the uncertainty in these estimates was compensated for by assigning a distribution to
these estimates in the probabilistic sensitivity analysis; the estimates assume the benefits of anastrozole continued out to 10 years from initiation of treatment.
bFrom the 68-
month median follow-up of ATAC trial patients (ATAC Trialists’ Group, 2005).
cFrom Kamby and Sengeløv (1997).
dFrom Moran and Haffty (2002).
eEstimated from the median
68-month follow-up data of ATAC trial patients (ATAC Trialists’ Group, 2005).
fFrom Stockler et al (2000).
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sfor the distribution of the incremental cost-effectiveness ratio
(ICER) derived from the simulation. The curve shows the
probability that the ICER is less than a specified cost per QALY
and, therefore, shows the probability that the ratio is cost-effective
relative to any chosen ICER threshold. The contribution of the
parameters to the variance of the ICER was also estimated.
In addition, a one-way sensitivity analysis was also carried out
whereby the parameters were varied individually and expressed as
a tornado chart.
The extent to which the uncertainty of parameters was explored
in the sensitivity analysis varied by parameter (see Tables 1–3).
ATAC trial data were used as the basis for determining the
uncertainty in efficacy parameters. An s.d. equalling 90% of the
mean or the variation in responses obtained from the physician
survey was used to determine the uncertainly in costs.
The impact of varying the duration of the benefit of anastrozole
was also examined. In the base-case analysis it was assumed that
the benefits of anastrozole would continue out to 10 years from
initiation of treatment. In the sensitivity analysis, two other
scenarios were explored. In the first scenario, the incremental
benefits of anastrozole were assumed to extend out to lifetime. In
the second scenario, it was assumed that the benefits of anastrozole
would be limited to the median duration of follow-up of the ATAC
trial (i.e. 6 years).
RESULTS
Clinical outcomes and costs
When the 5-year ATAC trial results were extrapolated to 25 years,
anastrozole and tamoxifen were associated with mean QALYs of
9.21 and 8.96 years, respectively, per patient. Anastrozole was also
associated with a longer projected (and discounted) overall mean
survival duration at 25 years (9.46 vs 9.23 life-years) and a higher
estimated (discounted) cumulative mean cost per patient at 25
years (d9935 vs d5620), respectively, compared with the tamoxifen
group. The per patient results are shown in Table 4. The higher
cumulative drug acquisition cost with anastrozole was partly offset
by lower costs for treating recurrences and palliative care (Table 4).
Consequently, the contribution of the acquisition cost of
anastrozole to total costs of care decreased from 50% at 5 years
to 36% at 25 years (Figure 4).
Cost-effectiveness findings
In a model anastrozole was estimated to lead to a gain of 0.244.
QALYs (or 0.231 life-years) at an additional cost of d4315 per
patient over an actuarial time horizon of 25 years. The results
partly arise due to the recurrences avoided with anastrozole
compared with tamoxifen and partly due to anastrozole’s superior
side effect profile compared with tamoxifen. This resulted in an
estimated incremental cost-effectiveness of anastrozole compared
with tamoxifen of d17656 per QALY gained. The incremental cost
per life-year gained was d18702. If the time horizon was limited to
5 or 10 years, then the corresponding cost per QALYs would be
d219950 and d47489, respectively. However, these results assume
no difference in costs and no difference in QALYs between
anastrozole and tamoxifen beyond these time horizons. A
simulation of 5000 runs of the model generated a cost-effectiveness
acceptability curve that indicated that there was a greater than 90%
probability that the cost per QALY gained with anastrozole would
be lower than d30000 and of the order of 65% that it would be
lower than d20000 (Figure 5). The incremental cost-effectiveness
ratio had a 95% non-parametric probability interval (PI) of d10280
to d39235 per QALY gained as reflected in the acceptability curve.
Table 2 Estimated costs of medical management, death and adverse
events used in the model
a
Cost (d) s.d.
b
Treatment/diagnosis (cost/event)
At treatment initiation 90 38
Diagnosis of recurrence 808 92
Treatment for local/regional recurrence 2606 2085
a
Treatment for distant recurrence 3563 2850
a
Follow-up and monitoring (cost/cycle)
Follow-up for local/regional recurrence 143 66
Follow-up for distant recurrence 199 95
Routine follow-up
Years 1 70 20
Years 2+ 43 17
Follow-up off treatment due to remission 24 18
Follow-up off treatment due to adverse events 51 43
Death (cost/year)
Death from breast cancer
c 3783 3404
Death from other causes 500 450
Adverse event
Fractures
d NA
Wrist 1463 NA
Spine 2915 NA
Hip 10682 NA
Ischaemic cerebrovascular event 6299 NA
Deep venous thromboembolism
e 2110 NA
Endometrial cancer 2245 NA
Hysterectomy 1873 NA
Ischaemic cardiovascular disease 3251 NA
Vaginal bleeding 1407 NA
Hot flushes 239 NA
Musculoskeletal disorders 533 NA
Mood disturbances 109 NA
Fatigue 20 NA
Nausea and vomiting 20 NA
Vaginal discharge 240 NA
Bisphosphonate treatment 1432 NA
Abbreviation: NA¼not applicable.
aOn the basis of physician survey, MEDTAP unit
cost database and NHS reference costs (Department of Health, 2003), except where
stated.
bCosts were assumed to follow a g-distribution.
cFrom Coyle et al (1999).
dFrom Iglesias et al (2002).
eFrom Gordois et al (2003).
Table 3 Deterministic mean utility scores used in the model (n¼23)
Probabilistic parameters
Utility item Mean (s.d.) ab
Disease-free state,
no adverse events
0.989 (0.010) 106.60 1.19
Common adverse events
(tamoxifen)
0.970 (0.041) 15.82 0.49
Common adverse events
(anastrozole)
0.962 (0.055) 10.66 0.42
Vaginal bleeding 0.933 (0.099) 5.02 0.36
Endometrial cancer 0.913 (0.101) 6.20 0.59
Wrist fracture 0.916 (0.099) 6.28 0.58
New contralateral breast
cancer
0.914 (0.097) 6.72 0.63
Local/regional recurrence 0.911 (0.098) 6.78 0.66
Deep vein thromboembolism 0.922 (0.107) 4.87 0.41
Pulmonary embolism 0.890 (0.166) 2.27 0.28
Spinal fracture 0.894 (0.189) 1.48 0.18
Hip fracture 0.858 (0.199) 1.78 0.29
Hormonal therapy for distant
recurrence
0.882 (0.105) 7.44 1.00
Chemotherapy for distant
recurrence
0.710 (0.254) 1.56 0.64
Current health 0.933 (0.069) 11.32 0.81
Hysterectomy 0.899 (0.101) 7.10 0.80
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sSensitivity analysis
The overall uncertainty of the ICER is represented by the
acceptability curve shown in Figure 3. All the parameters of the
model, including the utility values shown in Table 3, were included
in the probabilistic sensitivity analysis. Table 5 shows the
parameters that had the largest contribution to the variance of
the ICER in the probabilistic analysis. The table shows that the
ICERs are largely dependent on the parameters of the Weibull
regression, the probability of receiving bisphosphonate treatment,
the cost of bisphosphonate treatment and the proportion of
patients with a distant recurrence if relapsing. The results of the
model were robust to changes in key parameters and assumptions
in the sensitivity analysis including changes in fracture rates and
the parameters of the distributions assumed for costs and
probabilities. The regression coefficient of the Weibull time to
recurrence curve was the most sensitive parameter in the
stochastic analysis (Table 5). Other parameters that contributed
to the variation of the ICER were the probability of receiving
bisphosphonate and the cost of bisphosphonate treatment, that is,
how long patients receive it. Even allowing for the variability in the
utility values shown in Table 3, utilities had little impact on the
results. If a more pessimistic scenario for utilities was used, then
this would improve the results in favour of anastrozole because of
the latter’s superior efficacy and safety profile vs tamoxifen. These
corresponded to the results of the one-way sensitivity analysis.
The sensitivity analysis also examined the key base–case
assumption that the recurrence curves continued to show benefit
for anastrozole out to 10 years from initiation of treatment. When
the benefit was limited to the median duration of follow-up of the
ATAC trial (i.e. 6 years), the incremental cost-effectiveness ratio of
anastrozole vs tamoxifen was d23995 per QALY gained. When the
benefit of anastrozole was extended to the lifetime of the patient,
this value dropped to d14441 per QALY gained. A sensitivity
analysis was also performed using the alternative discount rates of
6% for costs and 1.5% for benefits as used by NICE in their
analysis. When these alternative discount rates were used, the cost
per QALY was reduced to d13185.
DISCUSSION
The analysis predicts that the benefit of anastrozole vs tamoxifen
as adjuvant therapy in postmenopausal women with HRþ early
breast cancer would translate over an actuarial 25-year time frame
into fewer breast cancer deaths and a consequent improvement in
survival (231 years gained) and quality of life (244 QALYs gained)
among a cohort of 1000 patients. The benefits were provided at an
incremental cost of d17656 per QALY (95% PI: d10280 to d39235)
gained. This value overlaps the d20000–d30000 range NICE has
defined as generally acceptable for new technologies (National
Institute for Health and Clinical Excellence, 2004). Given the recent
Table 4 Outcomes and cost of care per patient (discounted 25-year data)
Outcomes Cost (d)
Treatment QALYs (years) LYG (years) Drug Adverse events Follow-up Recurrence and palliative care Total
Anastrozole 9.206 9.464 3598 1347 2735 2254 9935
Tamoxifen 8.962 9.234 113 1366 1539 2603 5620
Abbreviations: LYG¼life-years gained; QALYs¼quality-adjusted life-years gained.
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Table 5 Sensitivity of the incremental cost/QALY ratio to parameters
Parameter
Contribution of
parameters to the
variability of the
ICER (%)
Rank
correlation
Weibull regression parameter (a
coefficient)
a
63.0  0.85
Weibull regression parameter (constant)
a 14.2 0.40
Cost of bisphosphonate treatment 5.5 0.25
Probability of receiving bisphosphonate
treatment
3.3 0.19
Proportion of patients with a distant
recurrence if relapsing
1.5 0.13
Utility of chemotherapy for distant cancer 1.9 0.15
Abbreviations: ICER¼incremental cost effectiveness ratio; QALY¼quality-adjusted
life year.
aCorrelated parameter.
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srecommendations that optimal adjuvant hormonal therapy for a
postmenopausal woman with HRþ early breast cancer should
include an aromatase inhibitor (such as anastrozole) as initial
therapy or after treatment with tamoxifen (Winer et al, 2005), such
findings will clearly be of relevance to healthcare decision makers
both in the United Kingdom and elsewhere.
The study was based on a Markov model for which a number of
assumptions were made. Consequently, as with any modelling
exercise, there are potential limitations that warrant consideration.
For example, the choice of time horizon could potentially influence
the results of the model. The study examined a 25-year time
horizon. This time frame was chosen because of the need to
consider the long-term benefits of treatment and because 25 years
would seem to represent a time point when the majority of patients
would have died. The incremental cost-effectiveness of d17656 per
QALY gained would be lower over longer time horizons and higher
over shorter time horizons. The reason for this relationship is that
most of the costs are drug related and occur early on, while the
survival effects occur predominantly later on.
The model also assumed that anastrozole provided incremental
benefit compared with tamoxifen out to 10 years from the
initiation of therapy. This assumption was based on the continuing
divergence of the recurrence curves observed during a median of
68 months’ follow-up in the ATAC Trialists’ Group (2005) and the
previous observation that tamoxifen provides a durable benefit
(Early Breast Cancer Trialists’ Group, 2005). This key assumption
did not appear to substantially influence the results. Indeed, when
this assumption was explored in the sensitivity analysis, it was
found that anastrozole retained an acceptable level of cost-
effectiveness (d23995 per QALY gained) when the benefit of
anastrozole was only extended to the end of the median duration
of follow-up in the ATAC trial (that is, 6 years). As for the base–
case analysis, this value remains within the generally accepted
threshold range for cost-effectiveness in the UK (Towse and
Pritchard, 2002).
Another potential limitation of the study is that the model relied
upon clinical expert opinion to define treatment from which
resource consumption was estimated. Despite the importance of
breast cancer in the national health policy of the United Kingdom,
there are few published data regarding the costs of treating breast
cancer. This is due to the lack of large administrative databases
linked with diagnosis that would provide the basis for analysis of
resource use, rendering most cost-effectiveness studies to rely on
published sources (Karnon and Brown, 2002). The inclusion of
real-life data from retrospective data sets or prospective natur-
alistic studies concerning adjuvant hormonal therapy in the United
Kingdom would therefore strengthen the model.
Another notable finding of the present study was that the cost-
effectiveness of anastrozole was not sensitive to differences in
adverse event rates, including the risk and associated costs of hip
fracture. This is despite the model making allowances for some
patients to receive prophylactic therapy during treatment with
anastrozole, and an assumption that the risk of hip fracture
extended for an additional 3 years beyond completion of therapy.
The fact that such allowances had little effect on the study findings
strengthens the stability of the model.
Two other studies have been carried out to evaluate the cost-
effectiveness of anastrozole vs tamoxifen in the primary adjuvant
breast cancer setting (Hillner, 2004; Locker, 2004). In the Locker
study, the incremental cost-effectiveness for anastrozole vs
tamoxifen was $23740 per QALY gained, a value that lies within
the threshold range that is generally accepted for reimbursement
in the USA ($50000–$100000 per QALY gained). In the Hillner
study, the incremental cost-effectiveness of anastrozole was
$75900 per QALY gained. However, neither of the findings is
readily comparable to the present investigation due to differences
in perspective (i.e. United States vs United Kingdom). Further-
more, while the Locker study has many similarities to the present
study with regards to model design, the Hillner study differed in
many respects such as in model structure, time horizon, healthcare
resource utilisation and study assumptions. For example, while
both the present analysis and the Locker study used the most
recent ATAC clinical trial data (5-year update) modelled over 25
years, the Hillner study used the 4-year update modelled over a
20-year time horizon. Moreover, Hillner’s model assumed an odds
ratio of 1.6 for hip fractures during anastrozole therapy, which is
higher than that seen in the completed treatment analysis of the
ATAC trial (1.2 (95% confidence interval, 0.74–1.93); P¼0.5)
(ATAC Trialists’ Group, 2005). The exact hip fracture odds ratio
was used in both the present study and the Locker model. At no
increased risk of hip fracture, the incremental cost-effectiveness of
anastrozole in Hillner’s model was $25300 per QALY gained,
which is comparable with the Locker result. While bearing in mind
the limitations of any direct comparison of the present study with
the above study, this equates to an incremental cost of d15150 per
QALY gained (exchange rate d1¼$1.67, October 2005), which is
similar to that found in the present study (d17656 per QALY
gained), falling within NICE’s generally accepted threshold range
for cost-effectiveness in the United Kingdom. Also, in the present
study, the results were robust to changes in the odds ratio for hip
fractures, with only a small increase in cost/QALY to d19077 if the
odds ratio increased to 1.6. This is largely due to the relatively low
incidence of hip fractures in both treatment arms and the
assumption of a low level of bisphosphonate usage in patients
receiving anastrozole in the United Kingdom.
Cost-effectiveness ratios are recognised by NICE as an
important aid to decision making. NICE also has a strong
preference for expressing health gains in terms of QALYs.
However, the NICE Appraisal Committee does not use a fixed
threshold for incremental cost-effectiveness ratios above which a
technology would automatically be defined as not cost-effective or
below which it would. On the other hand, comparisons with the
incremental cost-effectiveness ratios for previous treatments
recommended by NICE suggest that there is a high probability
that the incremental cost-effectiveness ratio for anastrozole
relative to tamoxifen would fall within the range that is likely to
be acceptable (i.e. od20000–d30000 per QALY gained) (Towse
and Pritchard, 2002; National Institute for Health and Clinical
Excellence, 2004). This substantiates that anastrozole represents
acceptable value for money, relative to tamoxifen, in the treatment
of postmenopausal women with HRþ early breast cancer.
Moreover, the cost-effectiveness of anastrozole compares favour-
ably with other cancer therapies recommended by NICE and
commonly used by the NHS, such as trastuzumab combination
therapy for treatment of advanced breast cancer (National Institute
for Health and Clinical Excellence, 2002) and imatinib for
treatment of chronic myeloid leukaemia (National Institute for
Health and Clinical Excellence, 2003). A 2003 budget impact study
estimated that use of anastrozole would cost an additional d19.3
million over 3 years, based on projected uptake of anastrozole over
tamoxifen of 17, 34 and 50% in each of the following 3 years,
respectively (Benedict and Christie, 2003). By comparison a NICE
assessment estimated that the treatment of all women with
osteoporosis would cost d0.9–1.5 billion over 5 years using
bisphosphonates (alendronate, etidronate, risedronate) and ralox-
ifene, increasing to more than d3.0 billion if teriparatide is
included (National Institute for Health and Clinical Excellence,
2005).
This study indicates whether reimbursement is warranted given
the existing evidence. However, the study does not assess whether
the existing evidence is sufficient for making those kinds of
decisions or whether additional research would be beneficial.
(Sculpher and Claxton, 2005). A formal value of information
analysis is outside the scope of this study. On the other hand, given
that the greatest source of uncertainty is the long-term extrapola-
tion of recurrence and mortality rates, it would seem appropriate
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ATAC becomes available.
CONCLUSIONS
The results of this study demonstrate that anastrozole is a cost-
effective alternative to tamoxifen (i.e. d17656 per QALY gained)
for the adjuvant treatment of postmenopausal women with HRþ
early breast cancer from the UK NHS perspective when compared
with NICE’s thresholds of d20000–d30000 per QALY. In
particular, the discounted incremental cost per QALY gained
compared favourably with other commonly accepted cancer
treatments. These results provide economic support for the recent
ASCO recommendations that optimal therapy for these women
should now include use of an aromatase inhibitor to lower the risk
of breast cancer recurrence (Winer et al, 2005). Anastrozole can
therefore be considered to be an effective and well-tolerated
therapy that provides value for money in the adjuvant treatment of
postmenopausal women with HRþ early breast cancer in the UK.
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